| 0 (0%) | 02-21 17:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.45 | 1-year : | 0.51 |
| Resists | First : | 0.39 | Second : | 0.43 |
| Pivot price | 0 | |||
| Supports | First : | 0.31 | Second : | 0.25 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 0.43 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AIH ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Fri, 20 Feb 2026
The AIH Transcript For February 18, 2026 - CBC
Tue, 17 Feb 2026
The AIH Transcript For February 13, 2026 - CBC
Fri, 05 Dec 2025
Genome—annotated bivariate analysis of shared heritability in autoimmune hepatitis with psychiatric comorbidity - Nature
Mon, 10 Nov 2025
Autoimmune hepatitis associated with other autoimmune diseases - EurekAlert!
Tue, 21 Oct 2025
Metabolomics in autoimmune hepatitis: progress and perspectives - Frontiers
Thu, 16 Oct 2025
Kezar mulls strategic options after clash with FDA on zetomipzomib's autoimmune hepatitis programme - FirstWord Pharma
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 48 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 294 (K) |
| Shares Short P.Month | 35 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.01 |
| Profit Margin | -5.5 % |
| Operating Margin | -11.3 % |
| Return on Assets (ttm) | -5.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 10.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 14.28 |
| EBITDA (p.s.) | -0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 74 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -2.78 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 0.02 |
| Price to Cash Flow | 0.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|